메뉴 건너뛰기




Volumn 162, Issue 6, 2010, Pages 1216-1223

Adalimumab therapy rapidly inhibits p38 mitogen-activated protein kinase activity in lesional psoriatic skin preceding clinical improvement

Author keywords

Adalimumab; P38 mitogen activated protein kinase; Psoriasis

Indexed keywords

ADALIMUMAB; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; STRESS ACTIVATED PROTEIN KINASE 1; TUMOR NECROSIS FACTOR ALPHA;

EID: 77952677598     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2010.09706.x     Document Type: Article
Times cited : (33)

References (34)
  • 1
    • 24344471811 scopus 로고    scopus 로고
    • British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005
    • Smith CH, Anstey AV, Barker JN et al. British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol 2005 153 : 486 497.
    • (2005) Br J Dermatol , vol.153 , pp. 486-497
    • Smith, C.H.1    Anstey, A.V.2    Barker, J.N.3
  • 2
    • 38549176118 scopus 로고    scopus 로고
    • Tumor necrosis factor antagonist mechanisms of action: A comprehensive review
    • Tracey D, Klareskog L, Sasso EH et al. Tumor necrosis factor antagonist mechanisms of action: A comprehensive review. Pharmacol Ther 2008 117 : 244 279.
    • (2008) Pharmacol Ther , vol.117 , pp. 244-279
    • Tracey, D.1    Klareskog, L.2    Sasso, E.H.3
  • 4
    • 0028233818 scopus 로고
    • Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions
    • Ettehadi P, Greaves MW, Wallach D et al. Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions. Clin Exp Immunol 1994 96 : 146 151.
    • (1994) Clin Exp Immunol , vol.96 , pp. 146-151
    • Ettehadi, P.1    Greaves, M.W.2    Wallach, D.3
  • 6
    • 0346848881 scopus 로고    scopus 로고
    • Changing paradigms in dermatology: Tumor necrosis factor alpha (TNF-alpha) blockade in psoriasis and psoriatic arthritis
    • Victor FC, Gottlieb AB, Menter A. Changing paradigms in dermatology: Tumor necrosis factor alpha (TNF-alpha) blockade in psoriasis and psoriatic arthritis. Clin Dermatol 2003 21 : 392 397.
    • (2003) Clin Dermatol , vol.21 , pp. 392-397
    • Victor, F.C.1    Gottlieb, A.B.2    Menter, A.3
  • 7
    • 35448935612 scopus 로고    scopus 로고
    • Biological and clinical effects of anti-TNFalpha treatment
    • Valesini G, Iannuccelli C, Marocchi E et al. Biological and clinical effects of anti-TNFalpha treatment. Autoimmun Rev 2007 7 : 35 41.
    • (2007) Autoimmun Rev , vol.7 , pp. 35-41
    • Valesini, G.1    Iannuccelli, C.2    Marocchi, E.3
  • 8
    • 33748936662 scopus 로고    scopus 로고
    • Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: Double-blind, randomized controlled trial and open-label extension study
    • Gordon KB, Langley RG, Leonardi C et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 2006 55 : 598 606.
    • (2006) J Am Acad Dermatol , vol.55 , pp. 598-606
    • Gordon, K.B.1    Langley, R.G.2    Leonardi, C.3
  • 9
    • 37349003068 scopus 로고    scopus 로고
    • Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial
    • Menter A, Tyring SK, Gordon K et al. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol 2008 58 : 106 115.
    • (2008) J Am Acad Dermatol , vol.58 , pp. 106-115
    • Menter, A.1    Tyring, S.K.2    Gordon, K.3
  • 10
    • 36849070806 scopus 로고    scopus 로고
    • Impact of adalimumab treatment on patient-reported outcomes: Results from a phase III clinical trial in patients with moderate to severe plaque psoriasis
    • Revicki DA, Willian MK, Menter A et al. Impact of adalimumab treatment on patient-reported outcomes: Results from a phase III clinical trial in patients with moderate to severe plaque psoriasis. J Dermatolog Treat 2007 18 : 341 350.
    • (2007) J Dermatolog Treat , vol.18 , pp. 341-350
    • Revicki, D.A.1    Willian, M.K.2    Menter, A.3
  • 11
    • 39049143819 scopus 로고    scopus 로고
    • Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)
    • Saurat JH, Stingl G, Dubertret L et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008 158 : 558 566.
    • (2008) Br J Dermatol , vol.158 , pp. 558-566
    • Saurat, J.H.1    Stingl, G.2    Dubertret, L.3
  • 12
    • 34548535119 scopus 로고    scopus 로고
    • Targeting TNFalpha rapidly reduces density of dendritic cells and macrophages in psoriatic plaques with restoration of epidermal keratinocyte differentiation
    • Marble DJ, Gordon KB, Nickoloff BJ. Targeting TNFalpha rapidly reduces density of dendritic cells and macrophages in psoriatic plaques with restoration of epidermal keratinocyte differentiation. J Dermatol Sci 2007 48 : 87 101.
    • (2007) J Dermatol Sci , vol.48 , pp. 87-101
    • Marble, D.J.1    Gordon, K.B.2    Nickoloff, B.J.3
  • 13
    • 27544465904 scopus 로고    scopus 로고
    • The tumour necrosis factor-alpha inhibitor adalimumab rapidly reverses the decrease in epidermal Langerhans cell density in psoriatic plaques
    • Gordon KB, Bonish BK, Patel T et al. The tumour necrosis factor-alpha inhibitor adalimumab rapidly reverses the decrease in epidermal Langerhans cell density in psoriatic plaques. Br J Dermatol 2005 153 : 945 953.
    • (2005) Br J Dermatol , vol.153 , pp. 945-953
    • Gordon, K.B.1    Bonish, B.K.2    Patel, T.3
  • 14
    • 14044252848 scopus 로고    scopus 로고
    • Adalimumab induces apoptosis of human monocytes: A comparative study with infliximab and etanercept
    • Shen C, van Assche G, Colpaert S et al. Adalimumab induces apoptosis of human monocytes: A comparative study with infliximab and etanercept. Aliment Pharmacol Ther 2005 21 : 251 258.
    • (2005) Aliment Pharmacol Ther , vol.21 , pp. 251-258
    • Shen, C.1    Van Assche, G.2    Colpaert, S.3
  • 15
    • 29744441553 scopus 로고    scopus 로고
    • Caspase activation and apoptosis induction by adalimumab: Demonstration in vitro and in vivo in a chimeric mouse model
    • Shen C, van Assche G, Rutgeerts P et al. Caspase activation and apoptosis induction by adalimumab: demonstration in vitro and in vivo in a chimeric mouse model. Inflamm Bowel Dis 2006 12 : 22 8.
    • (2006) Inflamm Bowel Dis , vol.12 , pp. 22-8
    • Shen, C.1    Van Assche, G.2    Rutgeerts, P.3
  • 16
    • 13244284850 scopus 로고    scopus 로고
    • The mitogen-activated protein kinases p38 and ERK1/2 are increased in lesional psoriatic skin
    • Johansen C, Kragballe K, Westergaard M et al. The mitogen-activated protein kinases p38 and ERK1/2 are increased in lesional psoriatic skin. Br J Dermatol 2005 152 : 37 42.
    • (2005) Br J Dermatol , vol.152 , pp. 37-42
    • Johansen, C.1    Kragballe, K.2    Westergaard, M.3
  • 17
    • 0036876857 scopus 로고    scopus 로고
    • Extracellular regulated kinase and c-Jun N-terminal kinase are activated in psoriatic involved epidermis
    • Takahashi H, Ibe M, Nakamura S et al. Extracellular regulated kinase and c-Jun N-terminal kinase are activated in psoriatic involved epidermis. J Dermatol Sci 2002 30 : 94 9.
    • (2002) J Dermatol Sci , vol.30 , pp. 94-9
    • Takahashi, H.1    Ibe, M.2    Nakamura, S.3
  • 18
    • 36148934536 scopus 로고    scopus 로고
    • Expression and localization of the activated mitogen-activated protein kinase in lesional psoriatic skin
    • Yu XJ, Li CY, Dai HY et al. Expression and localization of the activated mitogen-activated protein kinase in lesional psoriatic skin. Exp Mol Pathol 2007 83 : 413 418.
    • (2007) Exp Mol Pathol , vol.83 , pp. 413-418
    • Yu, X.J.1    Li, C.Y.2    Dai, H.Y.3
  • 19
    • 34447534298 scopus 로고    scopus 로고
    • Mitogen- and stress-activated protein kinase 2 and cyclic AMP response element binding protein are activated in lesional psoriatic epidermis
    • Funding AT, Johansen C, Kragballe K et al. Mitogen- and stress-activated protein kinase 2 and cyclic AMP response element binding protein are activated in lesional psoriatic epidermis. J Invest Dermatol 2007 127 : 2012 2019.
    • (2007) J Invest Dermatol , vol.127 , pp. 2012-2019
    • Funding, A.T.1    Johansen, C.2    Kragballe, K.3
  • 20
    • 33746139320 scopus 로고    scopus 로고
    • Mitogen- and stress-activated protein kinase 1 is activated in lesional psoriatic epidermis and regulates the expression of pro-inflammatory cytokines
    • Funding AT, Johansen C, Kragballe K et al. Mitogen- and stress-activated protein kinase 1 is activated in lesional psoriatic epidermis and regulates the expression of pro-inflammatory cytokines. J Invest Dermatol 2006 126 : 1784 1791.
    • (2006) J Invest Dermatol , vol.126 , pp. 1784-1791
    • Funding, A.T.1    Johansen, C.2    Kragballe, K.3
  • 21
    • 31144468296 scopus 로고    scopus 로고
    • Protein expression of TNF-alpha in psoriatic skin is regulated at a posttranscriptional level by MAPK-activated protein kinase 2
    • Johansen C, Funding AT, Otkjaer K et al. Protein expression of TNF-alpha in psoriatic skin is regulated at a posttranscriptional level by MAPK-activated protein kinase 2. J Immunol 2006 176 : 1431 1438.
    • (2006) J Immunol , vol.176 , pp. 1431-1438
    • Johansen, C.1    Funding, A.T.2    Otkjaer, K.3
  • 22
    • 2942530310 scopus 로고    scopus 로고
    • ERK and p38 MAPK-activated protein kinases: A family of protein kinases with diverse biological functions
    • Roux PP, Blenis J. ERK and p38 MAPK-activated protein kinases: A family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev 2004 68 : 320 344.
    • (2004) Microbiol Mol Biol Rev , vol.68 , pp. 320-344
    • Roux, P.P.1    Blenis, J.2
  • 23
    • 20544461306 scopus 로고    scopus 로고
    • Inverse regulation of the nuclear factor-kappaB binding to the p53 and interleukin-8 kappaB response elements in lesional psoriatic skin
    • Johansen C, Flindt E, Kragballe K et al. Inverse regulation of the nuclear factor-kappaB binding to the p53 and interleukin-8 kappaB response elements in lesional psoriatic skin. J Invest Dermatol 2005 124 : 1284 1292.
    • (2005) J Invest Dermatol , vol.124 , pp. 1284-1292
    • Johansen, C.1    Flindt, E.2    Kragballe, K.3
  • 24
    • 36249006497 scopus 로고    scopus 로고
    • The activity of caspase-1 is increased in lesional psoriatic epidermis
    • Johansen C, Moeller K, Kragballe K et al. The activity of caspase-1 is increased in lesional psoriatic epidermis. J Invest Dermatol 2007 127 : 2857 2864.
    • (2007) J Invest Dermatol , vol.127 , pp. 2857-2864
    • Johansen, C.1    Moeller, K.2    Kragballe, K.3
  • 25
    • 0021982891 scopus 로고
    • Increased DNA synthesis of uninvolved psoriatic epidermis is maintained in vitro
    • Kragballe K, Desjarlais L, Marcelo CL. Increased DNA synthesis of uninvolved psoriatic epidermis is maintained in vitro. Br J Dermatol 1985 112 : 263 270.
    • (1985) Br J Dermatol , vol.112 , pp. 263-270
    • Kragballe, K.1    Desjarlais, L.2    Marcelo, C.L.3
  • 26
    • 0037378429 scopus 로고    scopus 로고
    • 3 stimulates AP-1 DNA binding activity by a PI3-kinase/Ras/MEK/ERK1/2 and JNK1 dependent increase in c-Fos, Fra1 and c-Jun expression in human keratinocytes
    • 3 stimulates AP-1 DNA binding activity by a PI3-kinase/Ras/MEK/ERK1/2 and JNK1 dependent increase in c-Fos, Fra1 and c-Jun expression in human keratinocytes. J Invest Dermatol 2003 120 : 561 570.
    • (2003) J Invest Dermatol , vol.120 , pp. 561-570
    • Johansen, C.1    Kragballe, K.2    Henningsen, J.3
  • 27
    • 77952722897 scopus 로고    scopus 로고
    • U.S. Food and Drug Administration. Available at. (last accessed 8 February 2010)
    • U.S. Food and Drug Administration. Adalimumab Product Approval Information. Available at: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/ HowDrugsareDevelopedandApproved/ApprovalApplications/ TherapeuticBiologicApplications/ucm080610.htm (last accessed 8 February 2010).
    • Adalimumab Product Approval Information
  • 28
    • 13844294079 scopus 로고    scopus 로고
    • Signal transduction pathways in human epidermis
    • Iversen L, Johansen C, Kragballe K. Signal transduction pathways in human epidermis. Eur J Dermatol 2005 15 : 4 12.
    • (2005) Eur J Dermatol , vol.15 , pp. 4-12
    • Iversen, L.1    Johansen, C.2    Kragballe, K.3
  • 29
    • 43949126520 scopus 로고    scopus 로고
    • Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: Comparison among infliximab, etanercept, and adalimumab
    • Mitoma H, Horiuchi T, Tsukamoto H et al. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab. Arthritis Rheum 2008 58 : 1248 1257.
    • (2008) Arthritis Rheum , vol.58 , pp. 1248-1257
    • Mitoma, H.1    Horiuchi, T.2    Tsukamoto, H.3
  • 30
    • 36749070996 scopus 로고    scopus 로고
    • Mechanism of action of certolizumab pegol (CDP870): In vitro comparison with other anti-tumor necrosis factor alpha agents
    • Nesbitt A, Fossati G, Bergin M et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis 2007 13 : 1323 1332.
    • (2007) Inflamm Bowel Dis , vol.13 , pp. 1323-1332
    • Nesbitt, A.1    Fossati, G.2    Bergin, M.3
  • 31
    • 23444432216 scopus 로고    scopus 로고
    • TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques
    • Gottlieb AB, Chamian F, Masud S et al. TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J Immunol 2005 175 : 2721 2729.
    • (2005) J Immunol , vol.175 , pp. 2721-2729
    • Gottlieb, A.B.1    Chamian, F.2    Masud, S.3
  • 32
    • 21344475123 scopus 로고    scopus 로고
    • Regulation of p38 MAP kinase in CD4+ lymphocytes by infliximab therapy in patients with rheumatoid arthritis
    • Garfield BE, Krahl T, Appel S et al. Regulation of p38 MAP kinase in CD4+ lymphocytes by infliximab therapy in patients with rheumatoid arthritis. Clin Immunol 2005 116 : 101 107.
    • (2005) Clin Immunol , vol.116 , pp. 101-107
    • Garfield, B.E.1    Krahl, T.2    Appel, S.3
  • 33
    • 68949146860 scopus 로고    scopus 로고
    • Flow cytometric analysis of phospho-p38 mitogen-activated kinase (MAPK): P38 MAPK does not mediate the effect of adalimumab on peripheral T cell cytokine production in rheumatoid arthritis
    • Aerts NE, Ebo DG, Bridts CH et al. Flow cytometric analysis of phospho-p38 mitogen-activated kinase (MAPK): P38 MAPK does not mediate the effect of adalimumab on peripheral T cell cytokine production in rheumatoid arthritis. Cytokine 2009 47 : 178 184.
    • (2009) Cytokine , vol.47 , pp. 178-184
    • Aerts, N.E.1    Ebo, D.G.2    Bridts, C.H.3
  • 34
    • 34547582595 scopus 로고    scopus 로고
    • No effects of adalimumab therapy on the activation of NF-kappaB in lymphocytes from patients with severe rheumatoid arthritis
    • Semmler M, Seeck U, Neustadt B et al. No effects of adalimumab therapy on the activation of NF-kappaB in lymphocytes from patients with severe rheumatoid arthritis. Clin Rheumatol 2007 26 : 1499 1504.
    • (2007) Clin Rheumatol , vol.26 , pp. 1499-1504
    • Semmler, M.1    Seeck, U.2    Neustadt, B.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.